Souhaitez-vous accéder aux communiqués récents ?

Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C Cardiogenic shock SCAI Stage C has an in hospital mortality rate of 20-30% ...

Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in...

Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in...

Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury Strategy Ninety Nine Percent of the proceeds from both issuances to be used to buy BNB WARRINGTON, Pa., July ...

WARRINGTON, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) is pleased to announce a strategic partnership with Kraken, a leading...

WARRINGTON, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) is excited to announce it has entered into a $60 million securities...

1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old If istaroxime is approved in the US for...

The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients Windtree has...

Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of...

The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications    Primary endpoint of the study was met of...